Literature DB >> 23137948

Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer's disease in the presenilin 1 E280A kindred: a case-control study.

Eric M Reiman1, Yakeel T Quiroz, Adam S Fleisher, Kewei Chen, Carlos Velez-Pardo, Marlene Jimenez-Del-Rio, Anne M Fagan, Aarti R Shah, Sergio Alvarez, Andrés Arbelaez, Margarita Giraldo, Natalia Acosta-Baena, Reisa A Sperling, Brad Dickerson, Chantal E Stern, Victoria Tirado, Claudia Munoz, Rebecca A Reiman, Matthew J Huentelman, Gene E Alexander, Jessica B S Langbaum, Kenneth S Kosik, Pierre N Tariot, Francisco Lopera.   

Abstract

BACKGROUND: We have previously characterised functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's disease. To gain further knowledge on the preclinical phase of Alzheimer's disease, we sought to characterise structural and functional MRI, CSF, and plasma biomarkers in a cohort of young adults carrying a high-penetrance autosomal dominant mutation that causes early-onset Alzheimer's disease.
METHODS: Between January and August, 2010, 18-26-year-old presenilin 1 (PSEN1) E280A mutation carriers and non-carriers from the Colombian Alzheimer's Prevention Initiative Registry in Medellín Antioquia, Colombia, had structural MRI, functional MRI during associative memory encoding and novel viewing and control tasks, and cognitive assessments. Consenting participants also had lumbar punctures and venepunctures. Outcome measures were task-dependent hippocampal or parahippocampal activations and precuneus or posterior cingulate deactivations, regional grey matter reductions, CSF Aβ(1-42), total tau and phospho-tau(181) concentrations, and plasma Aβ(1-42) concentrations and Aβ(1-42):Aβ(1-40) ratios. Structural and functional MRI data were compared using automated brain mapping algorithms and search regions related to Alzheimer's disease. Cognitive and fluid biomarkers were compared using Mann-Whitney tests.
FINDINGS: 44 participants were included: 20 PSEN1 E280A mutation carriers and 24 non-carriers. The carrier and non-carrier groups did not differ significantly in their dementia ratings, neuropsychological test scores, or proportion of apolipoprotein E (APOE) ɛ4 carriers. Compared with non-carriers, carriers had greater right hippocampal and parahippocampal activation (p=0·001 and p<0·014, respectively, after correction for multiple comparisons), less precuneus and posterior cingulate deactivation (all p<0·010 after correction), and less grey matter in several parietal regions (all p<0·002 uncorrected and corrected p=0·009 in the right parietal search region). In the 20 participants (ten PSEN1 E280A mutation carriers and ten non-carriers) who had lumbar punctures and venepunctures, mutation carriers had higher CSF Aβ(1-42) concentrations (p=0·008) and plasma Aβ(1-42) concentrations (p=0·01) than non-carriers.
INTERPRETATION: Young adults at genetic risk for autosomal dominant Alzheimer's disease have functional and structural MRI findings and CSF and plasma biomarker findings consistent with Aβ(1-42) overproduction. Although the extent to which the underlying brain changes are either neurodegenerative or developmental remain to be determined, this study shows the earliest known biomarker changes in cognitively normal people at genetic risk for autosomal dominant Alzheimer's disease. FUNDING: Banner Alzheimer's Foundation, Nomis Foundation, Anonymous Foundation, Forget Me Not Initiative, Boston University Department of Psychology, Colciencias, National Institute on Aging, National Institute of Neurological Disorders and Stroke, and the State of Arizona.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23137948      PMCID: PMC4181671          DOI: 10.1016/S1474-4422(12)70228-4

Source DB:  PubMed          Journal:  Lancet Neurol        ISSN: 1474-4422            Impact factor:   44.182


  31 in total

1.  Synaptic activity regulates interstitial fluid amyloid-beta levels in vivo.

Authors:  John R Cirrito; Kelvin A Yamada; Mary Beth Finn; Robert S Sloviter; Kelly R Bales; Patrick C May; Darryle D Schoepp; Steven M Paul; Steven Mennerick; David M Holtzman
Journal:  Neuron       Date:  2005-12-22       Impact factor: 17.173

Review 2.  Alzheimer's prevention initiative: a proposal to evaluate presymptomatic treatments as quickly as possible.

Authors:  Eric M Reiman; Jessica B S Langbaum; Pierre N Tariot
Journal:  Biomark Med       Date:  2010-02       Impact factor: 2.851

3.  Clinical features of early-onset Alzheimer disease in a large kindred with an E280A presenilin-1 mutation.

Authors:  F Lopera; A Ardilla; A Martínez; L Madrigal; J C Arango-Viana; C A Lemere; J C Arango-Lasprilla; L Hincapíe; M Arcos-Burgos; J E Ossa; I M Behrens; J Norton; C Lendon; A M Goate; A Ruiz-Linares; M Rosselli; K S Kosik
Journal:  JAMA       Date:  1997-03-12       Impact factor: 56.272

4.  Spatial correlation between brain aerobic glycolysis and amyloid-β (Aβ ) deposition.

Authors:  Andrei G Vlassenko; S Neil Vaishnavi; Lars Couture; Dana Sacco; Benjamin J Shannon; Robert H Mach; John C Morris; Marcus E Raichle; Mark A Mintun
Journal:  Proc Natl Acad Sci U S A       Date:  2010-09-13       Impact factor: 11.205

5.  Reduced posterior cingulate mitochondrial activity in expired young adult carriers of the APOE ε4 allele, the major late-onset Alzheimer's susceptibility gene.

Authors:  Jon Valla; Roy Yaari; Andrew B Wolf; Yael Kusne; Thomas G Beach; Alex E Roher; Jason J Corneveaux; Matthew J Huentelman; Richard J Caselli; Eric M Reiman
Journal:  J Alzheimers Dis       Date:  2010       Impact factor: 4.472

6.  Molecular, structural, and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid, and memory.

Authors:  Randy L Buckner; Abraham Z Snyder; Benjamin J Shannon; Gina LaRossa; Rimmon Sachs; Anthony F Fotenos; Yvette I Sheline; William E Klunk; Chester A Mathis; John C Morris; Mark A Mintun
Journal:  J Neurosci       Date:  2005-08-24       Impact factor: 6.167

7.  Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia.

Authors:  Eric M Reiman; Kewei Chen; Gene E Alexander; Richard J Caselli; Daniel Bandy; David Osborne; Ann M Saunders; John Hardy
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-19       Impact factor: 11.205

Review 8.  The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics.

Authors:  John Hardy; Dennis J Selkoe
Journal:  Science       Date:  2002-07-19       Impact factor: 47.728

9.  Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E.

Authors:  E M Reiman; R J Caselli; L S Yun; K Chen; D Bandy; S Minoshima; S N Thibodeau; D Osborne
Journal:  N Engl J Med       Date:  1996-03-21       Impact factor: 91.245

10.  Amyloid beta from axons and dendrites reduces local spine number and plasticity.

Authors:  Wei Wei; Louis N Nguyen; Helmut W Kessels; Hiroaki Hagiwara; Sangram Sisodia; Roberto Malinow
Journal:  Nat Neurosci       Date:  2009-12-27       Impact factor: 24.884

View more
  202 in total

1.  Alzheimer's disease cerebrospinal fluid biomarker in cognitively normal subjects.

Authors:  Jon B Toledo; Henrik Zetterberg; Argonde C van Harten; Lidia Glodzik; Pablo Martinez-Lage; Luisella Bocchio-Chiavetto; Lorena Rami; Oskar Hansson; Reisa Sperling; Sebastiaan Engelborghs; Ricardo S Osorio; Hugo Vanderstichele; Manu Vandijck; Harald Hampel; Stefan Teipl; Abhay Moghekar; Marilyn Albert; William T Hu; Jose A Monge Argilés; Ana Gorostidi; Charlotte E Teunissen; Peter P De Deyn; Bradley T Hyman; Jose L Molinuevo; Giovanni B Frisoni; Gurutz Linazasoro; Mony J de Leon; Wiesje M van der Flier; Philip Scheltens; Kaj Blennow; Leslie M Shaw; John Q Trojanowski
Journal:  Brain       Date:  2015-07-27       Impact factor: 13.501

2.  Tau-dependent Kv4.2 depletion and dendritic hyperexcitability in a mouse model of Alzheimer's disease.

Authors:  Alicia M Hall; Benjamin T Throesch; Susan C Buckingham; Sean J Markwardt; Yin Peng; Qin Wang; Dax A Hoffman; Erik D Roberson
Journal:  J Neurosci       Date:  2015-04-15       Impact factor: 6.167

Review 3.  Biomarker modelling of early molecular changes in Alzheimer's disease.

Authors:  Ross W Paterson; Jamie Toombs; Catherine F Slattery; Jonathan M Schott; Henrik Zetterberg
Journal:  Mol Diagn Ther       Date:  2014-04       Impact factor: 4.074

4.  Autosomal Dominantly Inherited Alzheimer Disease: Analysis of genetic subgroups by Machine Learning.

Authors:  Diego Castillo-Barnes; Li Su; Javier Ramírez; Diego Salas-Gonzalez; Francisco J Martinez-Murcia; Ignacio A Illan; Fermin Segovia; Andres Ortiz; Carlos Cruchaga; Martin R Farlow; Chengjie Xiong; Neil R Graff-Radford; Peter R Schofield; Colin L Masters; Stephen Salloway; Mathias Jucker; Hiroshi Mori; Johannes Levin; Juan M Gorriz
Journal:  Inf Fusion       Date:  2020-01-07       Impact factor: 12.975

Review 5.  Role of HIV in amyloid metabolism.

Authors:  Mario Ortega; Beau M Ances
Journal:  J Neuroimmune Pharmacol       Date:  2014-05-10       Impact factor: 4.147

6.  Subjects harboring presenilin familial Alzheimer's disease mutations exhibit diverse white matter biochemistry alterations.

Authors:  Alex E Roher; Chera L Maarouf; Michael Malek-Ahmadi; Jeffrey Wilson; Tyler A Kokjohn; Ian D Daugs; Charisse M Whiteside; Walter M Kalback; Mimi P Macias; Sandra A Jacobson; Marwan N Sabbagh; Bernardino Ghetti; Thomas G Beach
Journal:  Am J Neurodegener Dis       Date:  2013-09-18

7.  Tau Accumulation in Clinically Normal Older Adults Is Associated with Hippocampal Hyperactivity.

Authors:  Willem Huijbers; Aaron P Schultz; Kathryn V Papp; Molly R LaPoint; Bernard Hanseeuw; Jasmeer P Chhatwal; Trey Hedden; Keith A Johnson; Reisa A Sperling
Journal:  J Neurosci       Date:  2018-11-27       Impact factor: 6.167

8.  Interaction between sleep-disordered breathing and apolipoprotein E genotype on cerebrospinal fluid biomarkers for Alzheimer's disease in cognitively normal elderly individuals.

Authors:  Ricardo S Osorio; Indu Ayappa; Janna Mantua; Tyler Gumb; Andrew Varga; Anne M Mooney; Omar E Burschtin; Zachary Taxin; Emmanuel During; Nicole Spector; Milton Biagioni; Elizabeth Pirraglia; Hiuyan Lau; Henrik Zetterberg; Kaj Blennow; Shou-En Lu; Lisa Mosconi; Lidia Glodzik; David M Rapoport; Mony J de Leon
Journal:  Neurobiol Aging       Date:  2013-12-27       Impact factor: 4.673

9.  Orexin-A is Associated with Increases in Cerebrospinal Fluid Phosphorylated-Tau in Cognitively Normal Elderly Subjects.

Authors:  Ricardo S Osorio; Emma L Ducca; Margaret E Wohlleber; Emily B Tanzi; Tyler Gumb; Akosua Twumasi; Samuel Tweardy; Clifton Lewis; Esther Fischer; Viachaslau Koushyk; Maria Cuartero-Toledo; Mohammed O Sheikh; Elizabeth Pirraglia; Henrik Zetterberg; Kaj Blennow; Shou-En Lu; Lisa Mosconi; Lidia Glodzik; Sonja Schuetz; Andrew W Varga; Indu Ayappa; David M Rapoport; Mony J de Leon
Journal:  Sleep       Date:  2016-06-01       Impact factor: 5.849

10.  Comparing positron emission tomography imaging and cerebrospinal fluid measurements of β-amyloid.

Authors:  Susan M Landau; Ming Lu; Abhinay D Joshi; Michael Pontecorvo; Mark A Mintun; John Q Trojanowski; Leslie M Shaw; William J Jagust
Journal:  Ann Neurol       Date:  2013-12       Impact factor: 10.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.